Abstract
Screening for abdominal aortic aneurysm (AAA) has been shown to be effective at reducing AAA-related mortality and is cost-effective. There are, however, significant variations in AAA screening protocols between healthcare systems and numerous challenges to be overcome. Further evidence of cost- and clinical effectiveness is likely to be required before there is widespread international adoption of AAA screening.